These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 34510527)

  • 1. Real-world effectiveness of guselkumab in patients with psoriasis: Health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial.
    Gerdes S; Bräu B; Hoffmann M; Korge B; Mortazawi D; Wiemers F; Wegner S; Personke Y; Gomez M; Sticherling M
    J Dermatol; 2021 Dec; 48(12):1854-1862. PubMed ID: 34510527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab.
    Gerdes S; Asadullah K; Hoffmann M; Korge B; Mortazawi D; Wegner S; Personke Y; Gomez M; Sticherling M
    J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):1568-1577. PubMed ID: 35569014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.
    Armstrong AW; Reich K; Foley P; Han C; Song M; Shen YK; You Y; Papp KA
    Am J Clin Dermatol; 2019 Feb; 20(1):155-164. PubMed ID: 30417277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness, safety and impact of guselkumab on sexuality and perceived stigmatization in patients with psoriasis in routine clinical practice: Week 28 results from the prospective German multicentre G-EPOSS study.
    Gerdes S; Ostendorf R; Süß A; Schadeck T; Taut F; Makuc J; Scharfenberger L; Jacobsen S; Trenkler N; Behrens J; Joks G; Tabori S; Mortazawi D
    J Eur Acad Dermatol Venereol; 2024 Apr; ():. PubMed ID: 38602225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.
    Reich K; Gordon KB; Strober BE; Armstrong AW; Miller M; Shen YK; You Y; Han C; Yang YW; Foley P; Griffiths CEM
    Br J Dermatol; 2021 Dec; 185(6):1146-1159. PubMed ID: 34105767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
    Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
    Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study.
    Reich K; Armstrong AW; Foley P; Song M; Miller M; Shen YK; You Y; Han C; Gordon KB
    Am J Clin Dermatol; 2020 Dec; 21(6):881-890. PubMed ID: 32910434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence.
    Medina-Catalán D; Riera P; Pagès-Puigdemont N; Masip M; López-Ferrer A; Vilarrasa E; Puig L
    Int J Clin Pharm; 2022 Jun; 44(3):725-730. PubMed ID: 35380392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
    Blauvelt A; Papp KA; Griffiths CE; Randazzo B; Wasfi Y; Shen YK; Li S; Kimball AB
    J Am Acad Dermatol; 2017 Mar; 76(3):405-417. PubMed ID: 28057360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.
    Papp KA; Blauvelt A; Kimball AB; Han C; Randazzo B; Wasfi Y; Shen YK; Li S; Griffiths CEM
    J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1515-1522. PubMed ID: 29512196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
    J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-life data over 36 weeks of guselkumab treatment in psoriasis patients: A single-center study from Turkey.
    Solak EÖ; Aba FC; Çınar SL; Kartal D; Borlu M
    J Cosmet Dermatol; 2024 May; 23(5):1912-1917. PubMed ID: 38491736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of guselkumab in patients with moderate-to-severe plaque psoriasis: a retrospective study from China.
    Huang H; Liu H; Zhu Z; Wang W; Liang B; Tang H; Yang S; Sheng Y; Sun L; Zhang X
    Eur J Dermatol; 2024 Feb; 34(1):73-78. PubMed ID: 38557462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and Safety of Guselkumab for the Treatment of Psoriasis in Real-World Settings at 52 weeks: A Retrospective, Observational, Multicenter Study from China.
    Yang J; Hu K; Li X; Hu J; Tan M; Zhang M; Kuang Y; Lv C; Chen J
    Dermatol Ther (Heidelb); 2023 Feb; 13(2):477-485. PubMed ID: 36481840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2.
    Kim BS; Jo SJ; Youn S; Reich K; Saadoun C; Chang CL; Yang YW; Huang YH; Tsai TF
    Dermatol Ther (Heidelb); 2023 Nov; 13(11):2721-2737. PubMed ID: 37750995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-life experience of guselkumab in patients with psoriasis.
    Snast I; Sherman S; Holzman R; Hodak E; Pavlovsky L
    Dermatol Ther; 2020 Nov; 33(6):e13964. PubMed ID: 32618384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Speed of clinical improvement in the real-world setting from patient-reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks.
    Reich A; Pinter A; Maul JT; Vender RB; Torres T; Brnabic A; Haustrup N; Reed C; Schuster C; Riedl E
    J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1825-1840. PubMed ID: 37147855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL).
    Lacour JP; Bewley A; Hammond E; Hansen JB; Horne L; Paul C; Reich K; Seneschal J; De Simone C; Sohrt A; Augustin M; Pellacani G
    Dermatol Ther (Heidelb); 2020 Oct; 10(5):1099-1109. PubMed ID: 32761560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS).
    Thaçi D; Pinter A; Sebastian M; Termeer C; Sticherling M; Gerdes S; Wegner S; Krampe S; Bartz H; Rausch C; Mensch A; Eyerich K
    Br J Dermatol; 2020 Aug; 183(2):265-275. PubMed ID: 31705526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.